What new evidence says about hormone therapy and heart risk

Interest in menopause hormone therapy has shifted again as newer research and updated guidance revisit an old question: does hormone therapy help the heart, harm it, or neither? The most careful answer is that the relationship depends on the type of therapy, when it is started, and the person taking it.

Recent coverage from AARP reflects a broader medical conversation now being echoed by cardiology and menopause experts. Hormone therapy can be an appropriate option for menopausal symptoms, but it is not considered a strategy for preventing cardiovascular disease. The newer discussion is less about using hormones to protect the heart and more about whether some modern regimens are safer than many people once believed when used for symptom relief in the right setting. https://www.aarp.org/health/conditions-treatments/hormone-therapy-heart-disease-risk/

What changed in the conversation

For years, hormone therapy carried a broad warning label that linked it with heart problems, blood clots and other risks. That warning grew out of earlier studies, especially research on older formulations and on women who were not close to menopause when treatment began. Since then, multiple reviews and professional statements have argued that those findings should not be applied too simplistically to every form of hormone therapy or to every patient. The FDA removed the boxed warnings from menopausal hormone therapy products in late 2025 and later finalized labeling changes in February 2026 after reviewing newer evidence. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

At the same time, the American Heart Association has emphasized that menopausal hormone therapy is intended to treat symptoms, not prevent cardiovascular disease. Its recent guidance also says decisions should account for the indication, cardiovascular and thrombotic risk, and patient preferences. https://professional.heart.org/-/media/PHD-Files/Education/Menopause-Therapy-Selection-Through-A-Cardiovascular-Lens-Infographic.pdf?sc_lang=en

Why the topic matters

Menopause is associated with changes in blood pressure, cholesterol, body fat distribution, insulin resistance and vascular function, all of which can affect long-term cardiovascular risk. That does not mean menopause itself causes heart disease, but it does mark a time when clinicians may pay closer attention to modifiable risk factors. Recent reviews describe menopause as a period when atherosclerotic risk can accelerate and when risk assessment may deserve a fresh look. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511246/

The practical implication is important: symptoms such as hot flashes, sleep disruption and mood changes may be the reason someone asks about hormone therapy, while heart health remains a separate issue that needs its own prevention plan. The two overlap, but they are not the same decision. https://professional.heart.org/-/media/PHD-Files/Education/Menopause-Therapy-Selection-Through-A-Cardiovascular-Lens-Infographic.pdf?sc_lang=en

What the evidence actually shows

Large reviews and meta-analyses continue to find that hormone therapy is effective for menopausal symptoms, but they do not support using it to lower the risk of heart attack or stroke. One meta-analysis found that menopausal hormone therapy did not reduce all-cause death or cardiovascular events and was associated with higher risks of stroke and venous thrombosis in postmenopausal women overall. https://pubmed.ncbi.nlm.nih.gov/38263123/

But newer studies have also complicated the old “one-size-fits-all” view. A recent AHA summary of a long-term Israeli study reported that contemporary hormone replacement therapy was not associated with higher rates of heart attack, stroke, blood clots or death among women ages 45 to 59 who started treatment around the time of menopause. Because this is observational research, it cannot prove that hormone therapy caused the outcomes; it can only show how outcomes compared in that group. https://newsroom.heart.org/news/long-term-study-finds-modern-hormone-replacement-therapy-not-linked-to-heart-disease-risk

That distinction matters. Earlier harm signals came largely from different populations, different ages and different formulations, including oral combined estrogen-progestin regimens used in settings that do not always match current prescribing. Newer reviews and professional guidance suggest that timing, route and dose may matter, and that transdermal estrogen may be preferred when thrombotic risk is a concern. https://pmc.ncbi.nlm.nih.gov/articles/PMC12511246/

What remains uncertain

Despite the more nuanced picture, several uncertainties remain. Researchers still do not have a simple answer for which patients benefit most, which regimen is safest for which risk profile, or how long any cardiovascular neutrality seen in some studies persists. Newer evidence is also not the same as proof of protection. In other words, some data suggest modern hormone therapy may not raise heart risk in selected patients, but that is very different from saying it improves heart health. https://newsroom.heart.org/news/long-term-study-finds-modern-hormone-replacement-therapy-not-linked-to-heart-disease-risk

There is also an important difference between systemic hormone therapy and local vaginal estrogen. The latter is used for genital or urinary symptoms and is absorbed much less into the body; AHA materials note that it has not been linked to higher heart, clot or cancer risk. That does not make it a universal choice, but it does help explain why treatments should be matched to the symptom being addressed. https://professional.heart.org/en/science-news/-/media/CE99245F3E5E4A319B12CE728B16B77D.ashx

What to discuss with a clinician

For people considering hormone therapy, the most useful discussion is not “Will this help my heart?” but rather “Is this the best treatment for my symptoms, and what are my cardiovascular and clotting risks?” The FDA advises that hormone therapy be considered with a healthcare professional, because benefits and risks vary by product and personal history. https://www.fda.gov/media/130242/download?attachment=

Topics worth raising include:

• whether symptoms are moderate or severe enough to justify treatment;
• personal history of blood clots, stroke, heart disease or breast cancer;
• whether the therapy would be oral, transdermal or local rather than systemic;
• how long treatment might be used and how it will be reviewed over time;
• what other steps are being taken to lower cardiovascular risk, such as managing blood pressure, cholesterol, blood sugar, sleep and physical activity. https://professional.heart.org/-/media/PHD-Files/Education/Menopause-Therapy-Selection-Through-A-Cardiovascular-Lens-Infographic.pdf?sc_lang=en

The bottom line

The newest evidence does not support hormone therapy as a heart-disease prevention tool. What it does suggest is that menopausal hormone therapy, used for symptom relief and chosen carefully, may be less broadly risky than older warnings implied for some patients. The safest takeaway is also the most restrained one: hormone therapy can be part of menopause care, but heart health still depends on a separate, individualized prevention strategy. https://professional.heart.org/-/media/PHD-Files/Education/Menopause-Therapy-Selection-Through-A-Cardiovascular-Lens-Infographic.pdf?sc_lang=en

If someone has chest pain, shortness of breath, sudden weakness, trouble speaking or other possible signs of a heart attack or stroke, they should seek urgent medical care right away.